Premium
Discarded portions of bone marrow aspirates are a new resource for patient‐derived mesenchymal stem and stromal cells
Author(s) -
Viola Shelton A.,
Aftab Chantel
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27936
Subject(s) - mesenchymal stem cell , bone marrow , medicine , stromal cell , stem cell , cancer research , population , ficoll , cell , immunology , pathology , microbiology and biotechnology , biology , in vitro , peripheral blood mononuclear cell , biochemistry , genetics , environmental health
Bone marrow‐derived mesenchymal stem and stromal cells (BM‐MSCs) protect malignant cells from chemotherapy and are important potential therapeutic targets. Isolating primary BM‐MSCs for research traditionally requires the sacrifice of valuable cell populations from within the same sample. To avoid this, we report here a resource for isolating patient‐derived BM‐MSCs from the red blood cell layer of ficoll gradients of bone marrow aspirates, a resource that has until now been universally discarded. This resource yields BM‐MSCs nearly identical to those obtained conventionally and includes cells with a more stem‐cell like nature. Obtaining primary BM‐MSCs in this way will likely expand opportunities to study this important cell population.